CD34<b>+</b>-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy

Mullanfiroze, Khushnuma; Lazareva, Arina; Chu, Jan; Williams, Lindsey; Burridge, Saskia; Silva, Juliana M Furtado; Chiesa, Robert; Rao, Kanchan; Lucchini, Giovanna; Ghorashian, Sara; O’Reilly, Maeve; Carpenter, Ben; Grandage, Victoria; Hough, Rachael; Roddie, Claire; Amrolia, Persis

doi:10.1182/bloodadvances.2022007572

Cited by 26 publications

(26 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the use of alloCD34 + HSCB has been reported in smaller series, 12,13 we highlight the safety and efficacy of a haploidentical alloCD34 + HSCB in our patient with severe hematotoxicity and concurrent life‐threatening infections following CD19‐CAR T‐cell therapy. Following the alloCD34 + HSCB, the patient engrafted, recovered from his life‐threatening infections, did not develop GVHD, and remains in CR.…”

mentioning

confidence: 75%

mentioning

confidence: 77%

“…While alloCD34 + HSCB is commonly used in the post‐transplant setting to rescue hematopoiesis, 11 there are limited data regarding its use following CAR T‐cell therapy. Recently, two small case series have highlighted the successful use of alloCD34 + HSCB 12,13 . Rapid hematopoietic recovery was noted following alloCD34 + HSCB without evidence of GVHD, and one patient developed CRS following the boost, presumably due to CD19 + B cells in the product.…”

mentioning

confidence: 99%

“…Recently, two small case series have highlighted the successful use of alloCD34 + HSCB. 12,13 Rapid hematopoietic recovery was noted following alloCD34 + HSCB without evidence of GVHD, and one patient developed CRS following the boost, presumably due to CD19 + B cells in the product.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Allogeneic CD34⁺ selected hematopoietic stem cell boost following CAR T‐cell therapy in a patient with prolonged cytopenia and active infection

Lipsitt

Beattie

Harstead

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Hematological toxicity (hematotoxicity) leading to peripheral cytopenias is a common long‐term adverse effect following the use of CD19‐chimeric antigen receptor (CD19‐CAR) T‐cell therapies. However, management remains unclear for patients whose cytopenias persist beyond 1 month after CAR T‐cell infusion. We present the case of a 21‐year old who received CD19‐CAR T‐cell therapy for relapse following a haploidentical transplant. He developed hematotoxicity and consequently multiple life‐threatening infections. We administered a CD34+ hematopoietic stem cell boost (HSCB) from his transplant donor, which led to hematopoietic recovery and resolution of his infections without any effect on the activity of CD19‐CAR T cells. CD34+ HSCB can be a safe and effective option to treat hematotoxicity following CD19‐CAR T‐cell therapy.

show abstract

mentioning

confidence: 75%

mentioning

confidence: 77%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Allogeneic CD34⁺ selected hematopoietic stem cell boost following CAR T‐cell therapy in a patient with prolonged cytopenia and active infection

Lipsitt

Beattie

Harstead

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…While alloCD34+ HSCB is commonly used in the post-transplant setting to rescue hematopoiesis (10), there is limited data regarding its use following CAR T-cell therapy. Recently, two small case series have highlighted the successful use of alloCD34+HSCB (11,12). Rapid hematopoietic recovery was noted following alloCD34+ HSCB without evidence of GVHD and one patient developed CRS following the boost, presumably due to CD19+ B cells in the product.…”

Section: Manuscriptmentioning

confidence: 99%

Allogeneic CD34+ Selected Hematopoietic Stem Cell Boost Following CAR T-cell Therapy in a Patient with Prolonged Cytopenia and Active Infection

Lipsitt

Beattie

Harstead

et al. 2022

Preprint

View full text Add to dashboard Cite

Hematological toxicity (hematotoxicity) is the most common long-term adverse effect following the use of CD19-chimeric antigen receptor (CD19-CAR) T-cell therapies. However, its management remains unclear. We present the case of a 21-year-old who received CD19-CAR T-cell therapy for relapse following a haploidentical transplant. He developed hematotoxicity and consequently multiple life-threatening infections. We administered a CD34+ hematopoietic stem cell boost (HSCB) from his transplant donor that led to hematopoietic recovery and resolution of his infections without any effect on the activity of CD19-CAR T cells. CD34+ HSCB can be a safe and effective option to treat hematotoxicity following CD19-CAR T-cell therapy.

show abstract

CAR‐T cell therapy

Franklin,

Pophali,

Jackson

et al. 2024

Molecular Hematology

View full text Add to dashboard Cite

CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy

Cited by 26 publications

References 19 publications

Allogeneic CD34⁺ selected hematopoietic stem cell boost following CAR T‐cell therapy in a patient with prolonged cytopenia and active infection

Allogeneic CD34⁺ selected hematopoietic stem cell boost following CAR T‐cell therapy in a patient with prolonged cytopenia and active infection

Allogeneic CD34+ Selected Hematopoietic Stem Cell Boost Following CAR T-cell Therapy in a Patient with Prolonged Cytopenia and Active Infection

CAR‐T cell therapy

Contact Info

Product

Resources

About

CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy

Cited by 26 publications

References 19 publications

Allogeneic CD34+ selected hematopoietic stem cell boost following CAR T‐cell therapy in a patient with prolonged cytopenia and active infection

Allogeneic CD34+ selected hematopoietic stem cell boost following CAR T‐cell therapy in a patient with prolonged cytopenia and active infection

Allogeneic CD34+ Selected Hematopoietic Stem Cell Boost Following CAR T-cell Therapy in a Patient with Prolonged Cytopenia and Active Infection

CAR‐T cell therapy

Contact Info

Product

Resources

About

Allogeneic CD34⁺ selected hematopoietic stem cell boost following CAR T‐cell therapy in a patient with prolonged cytopenia and active infection

Allogeneic CD34⁺ selected hematopoietic stem cell boost following CAR T‐cell therapy in a patient with prolonged cytopenia and active infection